http://rdf.ncbi.nlm.nih.gov/pubchem/reference/36042112

Outgoing Links

Predicate Object
contentType Journal Article
issn 1936-5233
pageRange 101707-
publicationName Translational Oncology
startingPage 101707
hasFundingAgency http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_cba2a6f3b06f9112dfb493ab5cff8354
http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_51a33cf70d418284c01eb772f438b7e5
http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_b5ad88fdb9d8a30d34a9b7f844c05af4
http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_aa048e23fd0358a0129a26ab8c57f3bb
http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_a500274ddff6e3ece320321eaa155c72
isSupportedBy http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_9d50f771df3f48b6fe60af06e1790826
http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_318e9d233917c440252e1a0f60575ca4
http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_255823c85fad514e8e3168b2ad75ba2b
bibliographicCitation Bai L, Li X, Yang Y, Zhao R, White EZ, Danaher A, Bowen NJ, Hinton CV, Cook N, Li D, Wu AY, Qui M, Du Y, Fu H, Kucuk O, Wu D. Bromocriptine monotherapy overcomes prostate cancer chemoresistance in preclinical models. Translational Oncology. 2023 Aug;34():101707. doi: 10.1016/j.tranon.2023.101707.
creator http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4fead195e84305e4eeedc00d1a1fca58
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4d3f2bbf810c3106070d810658cbcc99
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b86af13bd84cd617b597dd6be49b09eb
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a5b92823dcb113704ea568576c65f8cb
http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-4007-6590
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_bad84955ffdbe91fd4741abd4b921656
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_89718696b7066523167e2669fd930250
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_6e54ef912b24c477b5054c78b39a7874
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d4a6223441b0a48804177296d5b21574
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b5e11d5de60c5ef4e5e046d0091722eb
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4d37e1f55d5640fa9b933b8849702071
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_3d4b5936d7f7ff6af6efc9cc2d846b1b
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c0407034204fef0e812732086cd31c4f
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_8c0cf1cebb92ad6d2dfd176010a95389
http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-1609-6698
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_645bd5c7c983695f685c121707d165d3
date 202308
identifier https://pubmed.ncbi.nlm.nih.gov/37271121
https://doi.org/10.1016/j.tranon.2023.101707
https://pubmed.ncbi.nlm.nih.gov/PMC10248552
isPartOf https://portal.issn.org/resource/ISSN/1936-5233
http://rdf.ncbi.nlm.nih.gov/pubchem/journal/34574
language English
source https://www.crossref.org/
https://pubmed.ncbi.nlm.nih.gov/
title Bromocriptine monotherapy overcomes prostate cancer chemoresistance in preclinical models
discussesAsDerivedByTextMining http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_75be19437755fc2af3f5756d6bb1d737
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_c2b3a5ba99bc94e77229bab735b7776f
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8603
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID23676225
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_4364cf21c8950e29e0eef7c8157371bc
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_4a20a852de6e0b3ecac342b0499ddb5b
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_c3addd02e769f33d86f94bb13502ccd5
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_24fcc8ae2c4a3fc4fe2b5ecda59a20f4
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID31101
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID31100
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_bf99a94c673fe4e93461af6be7e99f9e
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_582d5f2f504253c89e3a8210d6134600
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/EC_2.7.13.3
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8983
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_52a517e173e6fa70285ded085be0d86f
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_f1b2452da84551fc91db93425b6a20d9

Total number of triples: 56.